Clene Inc (NQ: CLNN )

5.510 -0.340 (-5.81%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,155
Open 5.850
Bid (Size) 5.210 (1)
Ask (Size) 5.700 (5)
Prev. Close 5.850
Today's Range 5.430 - 5.990
52wk Range 3.818 - 12.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
Via Investor Brand Network

Performance

YTD
-6.29%
-6.29%
1 Month
-5.33%
-5.33%
3 Month
+8.46%
+8.46%
6 Month
-27.65%
-27.65%
1 Year
-47.62%
-47.62%

More News

Read More
Disruptions in Purine Metabolism Cited in Parkinson’s Development
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
Exposures Product Safety
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
Via NewMediaWire
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
Via NewMediaWire
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
Via Investor Brand Network
Exposures Product Safety
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
Via Investor Brand Network
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
Via Investor Brand Network
Exposures Product Safety
UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis
Via Investor Brand Network
Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.